RxDoctor Payments Data

Steven Laplante

Nurse Practitioner · Schenectady, NYNPI 1336318013

Payments from drug & device makers

$6,234in general payments, 2019–2025

Across 409 payments — averaging $15.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$988
  • Pfizer$680
  • Lundbeck LLC$565
  • Neurocrine Biosciences, Inc.$538
  • UCB, Inc.$451
  • Lilly USA, LLC$278
  • plus $3K from 40 others

What the payments were for

  • Food & beverage$6,12598%
  • Education$1102%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,234 in reported general payments places this provider in the 95th percentile of 4,112 nurse practitioner providers in New York.

See all nurse practitioner providers in New York

Medicare billing

Part B allowed, 2024
$43,941
Medicare patients
224
Services billed
725

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate42$49,621
Emgality PenGalcanezumab-Gnlm33$26,336
Ajovy AutoinjectorFremanezumab-Vfrm26$19,360
QuliptaAtogepant13$13,708
Aimovig AutoinjectorErenumab-Aooe17$13,140
Memantine Hcl247$5,970
Gabapentin311$4,064
Levetiracetam175$3,803
Lamotrigine ErLamotrigine13$2,636
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone15$2,319
Sumatriptan Succinate57$2,306
Primidone44$2,151
Pregabalin96$2,088
Divalproex Sodium ErDivalproex Sodium20$1,948
Donepezil Hcl183$1,601

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$680$49,62142 claims
AbbVieQulipta$988$13,70813 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil$76$1,47531 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,112 nurse practitioner providers in New York.

Other nurse practitioner in Schenectady

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →